• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Anika Therapeutics Inc.

Anika misses Q1 earnings by a penny

May 4, 2017 By Sarah Faulkner

Anika Therapeutics

Shares in Anika Therapeutics (NSDQ:ANIK) fell today after the orthopedics company missed expectations on Wall Street with its 1st quarter results. The Bedford, Mass.-based company posted profits of $5.5 million, or 37¢ per share, on sales of $23.4 million for the 3 months ended March 31, for bottom-line loss of -20.3% on sales growth of 4.9% compared […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Orthopedics Tagged With: Anika Therapeutics Inc.

Anika beats Q4 earnings, revenue estimates

February 16, 2017 By Sarah Faulkner

Anika Therapeutics

Shares in Anika Therapeutics (NSDQ:ANIK) fell today, even though the orthopedic medicines company beat expectations on Wall Street with its 4th quarter results. The Bedford, Mass.-based company posted profits of $8.1 million, or 54¢ per share, on sales of $28.7 million for the 3 months ended Dec. 31, for bottom-line loss of -26% on sales loss of -7% compared with […]

Filed Under: Featured, MassDevice Earnings Roundup, Orthopedics Tagged With: Anika Therapeutics Inc.

Anika Therapeutics wins CE Mark for tennis elbow injection

December 19, 2016 By Sarah Faulkner

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) said today that it won CE Mark approval in the European Union for its Orthovisc-T injection. The Bedford, Mass.-based company’s treatment is indicated to relieve pain and restore function in tendons affected by tennis elbow, or chronic lateral epicondylosis. The sodium hyaluronate injection promotes tendon gliding and repair at the site of the […]

Filed Under: Featured, Pain Management, Regulatory/Compliance, Wall Street Beat Tagged With: Anika Therapeutics Inc.

Anika Therapeutics wins CE Mark for Cingal knee treatment

March 28, 2016 By Fink Densford

Anika Therapeutics said today it won CE Mark approval in the European Union for its Cingal drug-combo designed to treat osteoarthritis-related knee pain. Cingal is a combined viscosupplement formulated with the company’s cross-linked sodium hyaluronate and triamcinolone hexacetonide, a steroid used to treat inflammation, the Bedford, Mass.-based company said. “The European approval of Cingal marks an […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Anika Therapeutics Inc.

Anika assigned to FDA's drug eval arm for Cingal approval

December 9, 2015 By Fink Densford

Anika Therapeutics today said the FDA’s Office of Combination Products assigned the company’s Cingal drug-combo to its Center for Drug Evaluation and Research arm to pursue premarket regulatory approval. Cingal is a combined viscosupplement formulated with the company’s cross-linked sodium hyaluronate and triamcinolone hexacetonide, a steroid used to treat inflammation, the company said. “While we […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Anika Therapeutics Inc.

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS